Biotech is next US-China flashpoint.

The geopolitical rivalry between Beijing and Washington is expanding into a new field: biotechnology. This shift could create fresh tensions even as American drug companies increasingly rely on China’s growing industry for new medicines. For years, China’s biotech sector was seen mainly as a low-cost manufacturing base, powered by a large domestic market. But sustained investment, lower costs, and faster development cycles have changed that view. The industry is now becoming a key area of competition between the two powers.